scholarly journals Economic Evaluation of Lapatinib in Her-2-Positive Metastatic Breast Cancer Patients in Egypt

2014 ◽  
Vol 17 (7) ◽  
pp. A642
Author(s):  
G. Elsisi ◽  
E. Mady ◽  
A.A. Abo Taleb
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Economic Evaluation ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Her 2

scholarly journals Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting

Data in Brief ◽  
2020 ◽  
Vol 29 ◽  
pp. 105194 ◽  
Author(s):  
Vakaramoko Diaby ◽  
Ching-Yu Wang ◽  
Hussain Alqhtani ◽  
Sascha van Boemmel-Wegmann ◽  
Askal Ayalew Ali ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Economic Evaluation ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Healthcare Setting ◽  
Breast Cancer Patients ◽  
Her 2

Circulating Tumor Cells in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab and Chemotherapy

2009 ◽  
Vol 24 (1) ◽  
pp. 1-10 ◽  
Author(s):  
Raquel A. Nunes ◽  
Xiaochun Li ◽  
Soonmo Peter Kang ◽  
Harold Burstein ◽  
Lisa Roberts ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Treatment Response ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Peripheral Blood ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Her 2

The detection of circulating tumor cells (CTCs) in peripheral blood may have important prognostic and predictive implications in breast cancer treatment. A limitation in this field has been the lack of a validated method of accurately measuring CTCs. While sensitivity has improved using RT-PCR, specificity remains a major challenge. The goal of this paper is to present a sensitive and specific methodology of detecting CTCs in women with HER-2-positive metastatic breast cancer, and to examine its role as a marker that tracks disease response during treatment with trastuzumab-containing regimens. The study included patients with HER-2-positive metastatic breast cancer enrolled on two different clinical protocols using a trastuzumab-containing regimen. Serial CTCs were measured at planned time points and clinical correlations were made. Immunomagnetic selection of circulating epithelial cells was used to address the specificity of tumor cell detection using cytokeratin 19 (CK19). In addition, the extracellular domain of the HER-2 protein (HER-2/ECD) was measured to determine if CTCs detected by CK19 accurately reflect tumor burden. The presence of CTCs at first restaging was associated with disease progression. We observed an association between CK19 and HER-2/ECD. The association of HER-2/ECD with clinical response followed a similar pattern to that seen with CK19. Finally, the absence of HER-2/ECD at best overall response and a change of HER-2/ECD from positive at baseline to negative at best overall response was associated with favorable treatment response. Our study supports the prognostic and predictive role of the detection of CTCs in treatment of HER-2-positive metastatic breast cancer patients. The association between CK19 and markers of disease burden is in line with the concept that CTCs may be a reliable measure of tumor cells in the peripheral blood of patients with metastatic breast cancer. The association of CTCs at first restaging with treatment failure indicates that CTCs may have a role as surrogate markers to monitor treatment response.

Longitudinal changes in serum her-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients

2004 ◽  
Vol 2 (3) ◽  
pp. 138-139
Author(s):  
M Pichon ◽  
A Bethune-Volters ◽  
M Labroquère ◽  
S Guepratte ◽  
K Hacene ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Longitudinal Changes ◽  
Her 2

ADVIA Centaur® Her-2/Neu Shows Value in Monitoring Patients with Metastatic Breast Cancer

2004 ◽  
Vol 19 (3) ◽  
pp. 175-182 ◽  
Author(s):  
D. Lüftner ◽  
C. Cheli ◽  
K. Mickelson ◽  
E. Sampson ◽  
K. Possinger
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Clinical Status ◽  
Metastatic Breast ◽  
Analytical Performance ◽  
Minimum Detectable Concentration ◽  
Breast Cancer Patients ◽  
Time Points ◽  
Her 2

Introduction The proteolytic breakdown product corresponding to the extracellular domain (ECD) of the HER-2/neu oncoprotein p185 is found in the circulation of healthy individuals and patients having cancers of epithelial origin. For the current evaluation we sought to determine the analytical performance as well as the clinical utility of the newly developed ADVIA Centaur® HER-2/neu assay (Bayer HealthCare LLC, Diagnostics Division, Tarrytown, NY, USA) in monitoring patients with metastatic breast cancer during the course of disease and treatment and to compare the obtained results with those of CA 15–3. Methods The analytical performance (including precision, normal range, interfering substances, minimum detectable concentration, dilution recovery, spiking recovery and high-dose hook effect) were determined. HER-2/neu and CA 15–3 values were measured in retrospective samples obtained from 59 patients with metastatic breast cancer undergoing treatment over a 6–12 month period. Serial changes in serum HER-2/neu and CA 15–3 were correlated with changes in clinical status on a visit-to-visit basis. For each pair of serial measurements, changes of equal to or greater than, or less than 15% for HER-2/neu and 21% for CA 15–3 were considered to indicate progression or lack of progression, respectively. Results The ADVIA Centaur HER-2/neu assay demonstrated within-run imprecision and total imprecision ranging from 3.0–5.6% and from 3.2–5.7%, respectively. The upper limit of normal was 15.2 ng/mL (90% CI: 14.2–17.0 ng/mL). No significant interference (<5%) was seen with bilirubins, hemoglobin, triglycerides and cholesterol or therapeutic drugs commonly present in the sera of breast cancer patients. The minimum detectable concentration (analytical sensitivity) was found to be 0.5 ng/mL. The patient population in the clinical study included breast cancer patients who responded to therapy (stable, partial or complete response) or had disease progression. HER-2/neu levels showed a concordance of 78.1% (82/105 restaging time points) with the clinical course of disease, whereas CA 15–3 levels showed a concordance of 76.2% (80/105 restaging time points). The concordance with clinical status increased to 85.7% (90/105 restaging time points) when both results were used in combination as a series test. Conclusions The ADVIA Centaur HER-2/neu assay provides excellent analytical performance for serial testing of serum HER-2/neu levels. The clinical data demonstrate the usefulness of serum HER-2/neu in monitoring metastatic breast cancer patients during treatment. Furthermore, the results indicate that serum HER-2/neu and CA 15–3 may be useful in identifying disease progression or therapeutic response in different subgroups of women with metastatic breast cancer.

Central Nervous System Metastases in HER‐2–Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors

2007 ◽  
Vol 12 (7) ◽  
pp. 766-773 ◽  
Author(s):  
Stefania Gori ◽  
Simonetta Rimondini ◽  
Verena De Angelis ◽  
Mariantonietta Colozza ◽  
Giancarlo Bisagni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Central Nervous System ◽  
Nervous System ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Central Nervous System Metastases ◽  
Her 2

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

2013 ◽  
Vol 9 (7) ◽  
pp. 955-957 ◽  
Author(s):  
Claudia Bighin ◽  
Paolo Pronzato ◽  
Lucia Del Mastro
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Trastuzumab Emtansine ◽  
Breast Cancer Patients ◽  
Her 2

First‐Line Chemotherapy for HER‐2–Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment

2007 ◽  
Vol 12 (11) ◽  
pp. 1288-1298 ◽  
Author(s):  
Alessandro Morabito ◽  
Maria Carmela Piccirillo ◽  
Katia Monaco ◽  
Carmen Pacilio ◽  
Francesco Nuzzo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Adjuvant Treatment ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
First Line ◽  
Her 2 ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document